Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001465 · ClinicalTrials.gov registry record
Study of the Disease Process of Lymphangioleiomyomatosis
A clinical trial of Lymphangioleiomyomatosis and Pneumothorax, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT00001465: Recruiting study of Lymphangioleiomyomatosis and Pneumothorax, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00001465 is a study of Lymphangioleiomyomatosis and Pneumothorax that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 2,000 participants, above the 630-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (217% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001465, a study of Lymphangioleiomyomatosis and Pneumothorax, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.
Primary Outcome
To define the molecular basis of the remarkable proliferation of immature appearing smooth muscle cells, which is the cause of many of the clinical manifestations, and perhaps thereby to improve our understanding of the mechanism of smooth muscle cell proliferation in other diseases, e.g., interstitial lung diseases, asthma, atherosclerosis, hypertension, and post-angioplastic coronary restenosis. To assess the contribution of proteins and genetic factors to cyst formation, airway obstruction, a
Conditions Studied
Interventions
- DEVICE Toshibia Aquilion One CT
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 1995-12-18 |
What NCT00001465 shows while recruiting
NCT00001465 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 630-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (217% higher).
The record links to 4 conditions, with Lymphangioleiomyomatosis appearing as the primary indexed condition, and to 1 intervention - of which Toshibia Aquilion One CT is the first listed.
NCT00001465 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001465 about?
NCT00001465 is a clinical study titled "Study of the Disease Process of Lymphangioleiomyomatosis". Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and mole...
What is the current status of trial NCT00001465?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 1995-12-18.
What conditions does trial NCT00001465 study?
This clinical trial studies the following conditions: Lymphangioleiomyomatosis, Pneumothorax, Tuberous Sclerosis, Lung Disease.
What interventions are being tested in trial NCT00001465?
The interventions under investigation include: Toshibia Aquilion One CT (DEVICE).
Who is sponsoring clinical trial NCT00001465?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001465 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphangioleiomyomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001465's enrollment target sits among peer trials
2,000 2nd of 10 the highest of 10 other Lymphangioleiomyomatosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphangioleiomyomatosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
RECRUITING · Phase 1
-
Safety and Durability of Sirolimus for Treatment of LAM
RECRUITING
-
TSC Biosample Repository and Natural History Database
RECRUITING
-
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
RECRUITING
-
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
RECRUITING · Phase 1
-
Feasibility of [11C]Acetate-PET in LAM and TSC
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
- NCT00349830 · 2,000 participants
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI